New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S. Vafseo tablets now shipping in the U.S. Plan to start Phase 3 trial in mid-2025 to potentially expand Vafseo label to include treatment of late-stage non-dialysis CKD patients Company to discuss business… Continue reading Akebia Therapeutics Announces Multiple Positive Business Updates
Tag: Morgan
Sling Therapeutics to Announce Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease at the 43rd Annual J.P. Morgan Healthcare Conference
ANN ARBOR, Mich., Jan. 13, 2025 /PRNewswire/ — Sling Therapeutics, Inc., a late-stage biopharmaceutical company focused on the development of an oral small molecule for the treatment of thyroid eye disease (TED), will announce topline data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe TED at the 43rd Annual… Continue reading Sling Therapeutics to Announce Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with Thyroid Eye Disease at the 43rd Annual J.P. Morgan Healthcare Conference
Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
– PRGN-2012 has potential to be first FDA-approved therapeutic for treatment of RRP, a rare and devastating chronic disease – – Company completed BLA submission for PRGN-2012 for treatment of adults with RRP – – Commercial readiness activities underway in anticipation of potential launch of PRGN-2012; Company started 2025 with approximately $100 million cash on-hand* with cash… Continue reading Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
— Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates — — Expect to achieve $2 billion in AYVAKIT revenue by 2030 — — BLU-808 demonstrates wide therapeutic window with rapid, robust and sustained tryptase reductions exceeding 80% in Phase 1 healthy volunteer study —… Continue reading Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
— Updating peak systemic mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT® (avapritinib) launch and evolving SM prevalence estimates — — Expect to achieve $2 billion in AYVAKIT revenue by 2030 — — BLU-808 demonstrates wide therapeutic window with rapid, robust and sustained tryptase reductions exceeding 80% in Phase 1 healthy volunteer study —… Continue reading Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 /PRNewswire/ — IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 43rd Annual J.P. Morgan Healthcare Conference and provided 2025 corporate guidance and program updates. 43rd Annual J.P. Morgan Healthcare ConferenceMonday, January 13th,… Continue reading IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results
FY 2024 revenue of ~$611 million and Q4 2024 revenue of ~$165 million, representing 9% growth sequentially PLEASANTON, Calif., Jan. 12, 2025 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2024. Preliminary,… Continue reading 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results
Clean Technica: Is Tesla In Trouble? Was Alignment With A Trump 2.0 Presidency A Profit Gamble?003798
Sign up for daily news updates from CleanTechnica on email. Or follow us on Google News! Tesla seemed as if it was on a smooth road trip looking ahead to the next four years. CEO Elon Musk single-handedly rallied voters in November’s win for the right-wing entourage of Donald J. Trump. Sure, the allegiance came… Continue reading Clean Technica: Is Tesla In Trouble? Was Alignment With A Trump 2.0 Presidency A Profit Gamble?003798
Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C., Jan. 10, 2025 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, at 3:45 p.m. (PT). A live audio webcast of the fireside chat will be available via… Continue reading Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference
David Schilansky Appointed Chief Financial Officer of Ariceum Therapeutics
BERLIN, Jan. 10, 2025 /PRNewswire/ — Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced the appointment of David Schilansky as Chief Financial Officer with immediate effect, taking over from Rainer Sturm, who will ensure a smooth transition. David has more than 25… Continue reading David Schilansky Appointed Chief Financial Officer of Ariceum Therapeutics